Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
Evolving concepts in the treatment of relapsing multiple sclerosis
G Comi, M Radaelli, PS Sørensen - The Lancet, 2017 - thelancet.com
In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The
increasing availability of effective disease-modifying therapies has shifted the aim of …
increasing availability of effective disease-modifying therapies has shifted the aim of …
Disease‐modifying treatments for multiple sclerosis–a review of approved medications
Background and purpose There is still no curative treatment for multiple sclerosis (MS), but
during the last 20 years eight different disease‐modifying compounds have been approved …
during the last 20 years eight different disease‐modifying compounds have been approved …
Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis
PA Muraro, M Pasquini, HL Atkins, JD Bowen… - JAMA …, 2017 - jamanetwork.com
Importance Autologous hematopoietic stem cell transplantation (AHSCT) may be effective in
aggressive forms of multiple sclerosis (MS) that fail to respond to standard therapies …
aggressive forms of multiple sclerosis (MS) that fail to respond to standard therapies …
[HTML][HTML] Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
G Giovannoni, B Turner, S Gnanapavan… - Multiple sclerosis and …, 2015 - Elsevier
The management of multiple sclerosis is becoming increasingly complex with the
emergence of new and more effective disease-modifying therapies (DMT). We propose a …
emergence of new and more effective disease-modifying therapies (DMT). We propose a …
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …
modifying therapies with diverse safety and efficacy profiles. The importance of early …
Disease-modifying therapies and infectious risks in multiple sclerosis
A Winkelmann, M Loebermann, EC Reisinger… - Nature Reviews …, 2016 - nature.com
Immunomodulatory and immunosuppressive treatments for multiple sclerosis (MS) are
associated with an increased risk of infection, which makes treatment of this condition …
associated with an increased risk of infection, which makes treatment of this condition …
Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab
Importance Alemtuzumab, a CD52-depleting monoclonal antibody, effectively inhibits
relapsing multiple sclerosis (MS) but is associated with a high incidence of secondary B-cell …
relapsing multiple sclerosis (MS) but is associated with a high incidence of secondary B-cell …
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition
Secondary progressive multiple sclerosis (SPMS) is the second most common form of
multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will …
multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will …
Immunological aspects of approved MS therapeutics
Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …
to disability in young adults. The outcome of the disease is unpredictable, and over time …